Male breast carcinoma

Summary

Male breast carcinoma (MONDO:0005628) is a cancer with 4 cohort genes (10 GWAS associations across 3 studies; 2 CIViC-evidence somatic drivers; 1 ClinVar predisposition record) and 104 clinical trials. Top therapeutic interventions include lapatinib, tamoxifen citrate, and vorinostat.

At a glance

• Classification: Cancer
• Cohort genes: 4
• GWAS associations: 10
• ClinVar variants: 1
• Clinical trials: 104

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	male breast carcinoma
Mondo ID	MONDO:0005628
EFO	EFO:0006861
MeSH	D018567
DOID	DOID:1614
NCIT	C3862
SNOMED CT	372095001
UMLS	C0238033
MedGen	68650
GARD	0009312
Anatomy (UBERON)	UBERON:0016410
Is cancer (heuristic)	yes

Also known as: breast cancer in men · breast cancer, male · carcinoma of Male breast · carcinoma of male breast · carcinoma of the Male breast · Male breast cancer · male breast cancer · Male breast carcinoma · male breast carcinoma

Data availability: 1 ClinVar variant · 10 GWAS associations (3 studies).

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › breast carcinoma › male breast carcinoma

Related subtypes (12): nipple carcinoma, bilateral breast carcinoma, female breast carcinoma, sporadic breast cancer, breast carcinoma in situ, breast adenocarcinoma, breast carcinoma by gene expression profile, invasive breast carcinoma, Ehrlich tumor carcinoma, hereditary breast carcinoma, cribriform carcinoma of breast, hormone-resistant breast carcinoma

Genetics & variants

GWAS landscape

10 GWAS associations across 3 studies. Top hits map to 6 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs3803662	4e-15	CASC16	?	1.5
rs1314913	3e-13	RAD51B	?	1.57
rs78540526	1e-11	LINC01488 - PNCRNA-D	T	1.61
rs554219	3e-11	LINC01488 - PNCRNA-D	G	1.45
rs9383938	3e-09	ESR1	T	1.47
rs9397437	5e-09	CCDC170 - ESR1	A	1.5
rs3757322	6e-09	CCDC170	G	1.26
rs75915166	8e-08	LINC01488 - PNCRNA-D	A	1.53
rs2183271	3e-07	MLLT10	C	1.22
rs903263	1e-06	PRKACB	?	1.27

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST011526	Maguire S	2020	1,380	3,620	Common susceptibility loci for male breast cancer.
GCST001690	Orr N	2012	823	2,795	Genome-wide association study identifies a common variant in RAD51B associated with male breast cancer risk.
GCST90481501	Verma A	2024	232	417,314	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	1
Tier 3: regulatory	2
Tier 4: intronic/intergenic	7

MAF distribution

Bucket	Variants
common (>=0.05)	10
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	0

Functional consequences

Consequence	Count
intron_variant	3
intergenic_variant	3
regulatory_region_variant	2
non_coding_transcript_exon_variant	1
3_prime_UTR_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs3803662	16	52552429	A>C,G,T	0.05	non_coding_transcript_exon_variant	CASC16	4e-15	Tier 4: intronic/intergenic
rs1314913	14	68232877	C>T	0.05	intron_variant	RAD51B	3e-13	Tier 4: intronic/intergenic
rs78540526	11	69516650	C>T	0.05	regulatory_region_variant	LINC01488 - PNCRNA-D	1e-11	Tier 3: regulatory
rs554219	11	69516874	C>A,G,T	0.05	intergenic_variant	LINC01488 - PNCRNA-D	3e-11	Tier 4: intronic/intergenic
rs9383938	6	151666222	G>T	0.05	intergenic_variant	ESR1	3e-09	Tier 4: intronic/intergenic
rs9397437	6	151631197	G>A	0.05	intergenic_variant	CCDC170 - ESR1	5e-09	Tier 4: intronic/intergenic
rs3757322	6	151621059	T>A,G	0.05	3_prime_UTR_variant	CCDC170	6e-09	Tier 2: splice/UTR
rs75915166	11	69564393	C>A	0.05	regulatory_region_variant	LINC01488 - PNCRNA-D	8e-08	Tier 3: regulatory
rs2183271	10	21668300	T>C	0.05	intron_variant	MLLT10	3e-07	Tier 4: intronic/intergenic
rs903263	1	84156830	G>A,T	0.05	intron_variant	PRKACB	1e-06	Tier 4: intronic/intergenic

ClinVar germline variants

1 retrieved; paginated sample, class counts are floors:

1 benign

ClinVar	Variant (HGVS)	Gene	Classification	Review
51169	NM_000059.4(BRCA2):c.1662T>G (p.Cys554Trp)	BRCA2	Benign	reviewed by expert panel

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 13 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Somatic driver evidence (intOGen + CIViC, cohort fanout)

Gene	intOGen role	Cancer types	CIViC
BRCA2	LoF	BLCA,BRCA,CESC,CHOL,HCC,HNSC,LUSC,MBL,OVT,PAAD,PRAD,PROSTATE,RCC,VULVA	CIViC #7
RAD51B			CIViC #4763

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
BRCA2	Orphanet:1331	Familial prostate cancer
BRCA2	Orphanet:1333	Familial pancreatic carcinoma
BRCA2	Orphanet:145	Hereditary breast and/or ovarian cancer syndrome
BRCA2	Orphanet:178	Chordoma
BRCA2	Orphanet:227535	Hereditary breast cancer
BRCA2	Orphanet:319462	Inherited cancer-predisposing syndrome due to biallelic BRCA2 mutations
BRCA2	Orphanet:440437	Familial colorectal cancer Type X
BRCA2	Orphanet:654	Nephroblastoma
BRCA2	Orphanet:667662	Breast implant-associated anaplastic large cell lymphoma
BRCA2	Orphanet:694963	Inflammatory breast cancer
BRCA2	Orphanet:70567	Cholangiocarcinoma
BRCA2	Orphanet:84	Fanconi anemia
PRKACB	Orphanet:289	Ellis Van Creveld syndrome

Cohort genes → proteins

4 cohort genes, 4 distinct canonical proteins.

Evidence partition

Subset	Genes
gwas_only	3
multi_evidence	1

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
BRCA2	HGNC:1101	ENSG00000139618	P51587	Breast cancer type 2 susceptibility protein	clinvar
TOX3	HGNC:11972	ENSG00000103460	O15405	TOX high mobility group box family member 3	gwas
PRKACB	HGNC:9381	ENSG00000142875	P22694	cAMP-dependent protein kinase catalytic subunit beta	gwas
RAD51B	HGNC:9822	ENSG00000182185	O15315	DNA repair protein RAD51 homolog 2	gwas

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
BRCA2	Breast cancer type 2 susceptibility protein	Involved in double-strand break repair and/or homologous recombination.
TOX3	TOX high mobility group box family member 3	Transcriptional coactivator of the p300/CBP-mediated transcription complex.
PRKACB	cAMP-dependent protein kinase catalytic subunit beta	Mediates cAMP-dependent signaling triggered by receptor binding to GPCRs.
RAD51B	DNA repair protein RAD51 homolog 2	Involved in the homologous recombination repair (HRR) pathway of double-stranded DNA breaks arising during DNA replication or induced by DNA-damaging agents.

Protein-family classification

Druggable: 1 · Difficult: 0 · Unknown: 3 · Druggable fraction: 0.25

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Kinase	1	6.9×	0.273
Other/Unknown	3	1.3×	0.404

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
BRCA2	Other/Unknown	no		BRCA2_repeat, NA-bd_OB-fold, BRCA2_OB_1
TOX3	Other/Unknown	no		HMG_box_dom, HMG_box_dom_sf, TOX_HMG-box_domain
PRKACB	Kinase	yes	2.7.11.11	Prot_kinase_dom, AGC-kinase_C, Ser/Thr_kinase_AS
RAD51B	Other/Unknown	no		AAA+_ATPase, Rad51_C, DNA_recomb/repair_RecA-like

Expression context

Cohort genes with no expression data: 0.

4 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	4
unknown	0

Top tissues across cohort

Tissue	Cohort genes
male germ line stem cell (sensu Vertebrata) in testis	2
secondary oocyte	1
ventricular zone	1
colonic mucosa	1
mucosa of sigmoid colon	1
pancreatic ductal cell	1
Brodmann (1909) area 23	1
endothelial cell	1
parietal lobe	1
buccal mucosa cell	1
sural nerve	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
BRCA2	184	ubiquitous	marker	male germ line stem cell (sensu Vertebrata) in testis, secondary oocyte, ventricular zone
TOX3	220	broad	marker	mucosa of sigmoid colon, pancreatic ductal cell, colonic mucosa
PRKACB	293	ubiquitous	marker	endothelial cell, Brodmann (1909) area 23, parietal lobe
RAD51B	193	ubiquitous	marker	sural nerve, buccal mucosa cell, male germ line stem cell (sensu Vertebrata) in testis

Protein interactions among cohort

Intra-cohort edges: 3.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
PRKACB	7,400
BRCA2	4,839
RAD51B	2,993
TOX3	1,454

Intra-cohort edges

A	B	Sources
BRCA2	RAD51B	string_interaction
BRCA2	TOX3	string_interaction
RAD51B	TOX3	string_interaction

Structural data

PDB: 2 · AlphaFold-only: 2 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
BRCA2	P51587	14
RAD51B	O15315	5

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
PRKACB	P22694	95.61
TOX3	O15405	60.22

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 105. Enrichment computed across 4 evidence-associated genes (3 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Impaired BRCA2 binding to PALB2	2	304.5×	3e-04	BRCA2, RAD51B
Defective homologous recombination repair (HRR) due to BRCA1 loss of function	2	282.0×	3e-04	BRCA2, RAD51B
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function	2	282.0×	3e-04	BRCA2, RAD51B
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function	2	282.0×	3e-04	BRCA2, RAD51B
Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)	2	262.5×	3e-04	BRCA2, RAD51B
Homologous DNA Pairing and Strand Exchange	2	253.8×	3e-04	BRCA2, RAD51B
Resolution of D-loop Structures through Holliday Junction Intermediates	2	200.3×	5e-04	BRCA2, RAD51B
Presynaptic phase of homologous DNA pairing and strand exchange	2	181.3×	5e-04	BRCA2, RAD51B
HDR through Homologous Recombination (HRR)	2	126.9×	9e-04	BRCA2, RAD51B
Impaired BRCA2 translocation to the nucleus	1	1268.9×	0.007	BRCA2
Impaired BRCA2 binding to SEM1 (DSS1)	1	1268.9×	0.007	BRCA2
Factors involved in megakaryocyte development and platelet production	2	44.3×	0.007	PRKACB, RAD51B
PKA-mediated phosphorylation of key metabolic factors	1	761.3×	0.011	PRKACB
HDL assembly	1	475.8×	0.016	PRKACB
ROBO receptors bind AKAP5	1	423.0×	0.017	PRKACB
Regulation of glycolysis by fructose 2,6-bisphosphate metabolism	1	317.2×	0.018	PRKACB
Defective homologous recombination repair (HRR) due to PALB2 loss of function	1	317.2×	0.018	BRCA2
CREB1 phosphorylation through the activation of Adenylate Cyclase	1	292.8×	0.018	PRKACB
HDR through MMEJ (alt-NHEJ)	1	292.8×	0.018	BRCA2
Glucose metabolism	1	292.8×	0.018	PRKACB
Diseases of DNA Double-Strand Break Repair	1	271.9×	0.018	BRCA2
Defective homologous recombination repair (HRR) due to BRCA2 loss of function	1	271.9×	0.018	BRCA2
Rap1 signalling	1	237.9×	0.018	PRKACB
Plasma lipoprotein assembly	1	237.9×	0.018	PRKACB
PKA activation in glucagon signalling	1	223.9×	0.018	PRKACB
Triglyceride metabolism	1	223.9×	0.018	PRKACB
PKA activation	1	211.5×	0.018	PRKACB
Resolution of D-Loop Structures	1	211.5×	0.018	BRCA2
PKA-mediated phosphorylation of CREB	1	190.3×	0.018	PRKACB
Diseases of DNA repair	1	190.3×	0.018	BRCA2

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 4 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
mitotic recombination-dependent replication fork processing	1	2106.5×	0.012	BRCA2
double-strand break repair via homologous recombination	2	78.0×	0.012	BRCA2, RAD51B
negative regulation of mammary gland epithelial cell proliferation	1	842.6×	0.015	BRCA2
blastocyst growth	1	702.2×	0.015	RAD51B
establishment of protein localization to telomere	1	526.6×	0.015	BRCA2
response to UV-C	1	421.3×	0.015	BRCA2
high-density lipoprotein particle assembly	1	421.3×	0.015	PRKACB
telomere maintenance via recombination	1	383.0×	0.015	BRCA2
regulation of protein processing	1	383.0×	0.015	PRKACB
somite development	1	280.9×	0.016	RAD51B
regulation of DNA damage checkpoint	1	280.9×	0.016	BRCA2
inner cell mass cell proliferation	1	247.8×	0.016	BRCA2
centrosome duplication	1	234.1×	0.016	BRCA2
response to X-ray	1	221.7×	0.016	BRCA2
female gonad development	1	200.6×	0.016	BRCA2
dorsal/ventral neural tube patterning	1	200.6×	0.016	PRKACB
vascular endothelial cell response to laminar fluid shear stress	1	183.2×	0.016	PRKACB
hematopoietic stem cell proliferation	1	162.0×	0.016	BRCA2
oocyte maturation	1	150.5×	0.016	BRCA2
positive regulation of G2/M transition of mitotic cell cycle	1	150.5×	0.016	RAD51B
male meiosis I	1	145.3×	0.016	BRCA2
response to gamma radiation	1	145.3×	0.016	BRCA2
reciprocal meiotic recombination	1	140.4×	0.016	RAD51B
renal water homeostasis	1	127.7×	0.017	PRKACB
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	1	123.9×	0.017	BRCA2
positive regulation of mitotic cell cycle	1	117.0×	0.017	BRCA2
negative regulation of smoothened signaling pathway	1	113.9×	0.017	PRKACB
regulation of cytokinesis	1	105.3×	0.017	BRCA2
cellular response to ionizing radiation	1	102.8×	0.017	BRCA2
nucleotide-excision repair	1	95.8×	0.018	BRCA2

Therapeutics

Drugs indicated for this disease

0 approved, 4 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Exemestane	Phase 3 (in late-stage trials)
Paclitaxel	Phase 3 (in late-stage trials)
Tamoxifen	Phase 3 (in late-stage trials)
Trastuzumab	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Abemaciclib, Aldesleukin, Anastrozole, Azacitidine, Becatecarin, Bevacizumab, Busulfan, Capecitabine, Carboplatin, Degarelix, Doconexent, Entinostat, Filgrastim, Gefitinib, Icosapent, Ixabepilone, Melphalan, Pegfilgrastim, Pembrolizumab, Pemetrexed, Romidepsin, Saracatinib, Sargramostim, Thiotepa, Triapine, Vorinostat.

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 3

Druggability breadth: 1 of 4 evidence-associated genes (25%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
PRKACB	CAPIVASERTIB

Top cohort targets by molecule count

Symbol	Molecules	Max phase
PRKACB	19	4
BRCA2	0	0
TOX3	0	0
RAD51B	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
CAPIVASERTIB	4	PRKACB
DASATINIB	4	PRKACB
MIDOSTAURIN	4	PRKACB
FASUDIL	3	PRKACB
AFURESERTIB	3	PRKACB
ENZASTAURIN	3	PRKACB
LESTAURTINIB	3	PRKACB
RUBOXISTAURIN	3	PRKACB
UCN-01	2	PRKACB
BMS-754807	2	PRKACB
ELLAGIC ACID	2	PRKACB
UPROSERTIB	2	PRKACB
BMS-690514	2	PRKACB
R-406	2	PRKACB
AT-9283	2	PRKACB
PF-03758309	1	PRKACB
AT-13148	1	PRKACB
GSK-690693	1	PRKACB
AST-487	1	PRKACB

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
PRKACB	391	Binding:385, Functional:6

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
PRKACB	2.7.11.11	cAMP-dependent protein kinase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
PRKACB	391

Pharmacogenomics

Cohort genes with a PharmGKB record: 4; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Drug repurposing candidates

19 approved/phased drugs hit cohort targets but don’t yet appear in disease-level clinical trials. Target-inhibition rationale is strongest for cancer driver genes; a bioactivity hit is a screening signal, not a treatment claim.

Compound	Max phase	Cohort target (bioactivity)
CAPIVASERTIB	4	PRKACB
DASATINIB	4	PRKACB
MIDOSTAURIN	4	PRKACB
FASUDIL	3	PRKACB
AFURESERTIB	3	PRKACB
ENZASTAURIN	3	PRKACB
LESTAURTINIB	3	PRKACB
RUBOXISTAURIN	3	PRKACB
UCN-01	2	PRKACB
BMS-754807	2	PRKACB
ELLAGIC ACID	2	PRKACB
UPROSERTIB	2	PRKACB
BMS-690514	2	PRKACB
R-406	2	PRKACB
AT-9283	2	PRKACB
PF-03758309	1	PRKACB
AT-13148	1	PRKACB
GSK-690693	1	PRKACB
AST-487	1	PRKACB

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	1	PRKACB
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	3	BRCA2, TOX3, RAD51B

Undrugged target profiles

3 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
BRCA2	0	—
TOX3	0	—
RAD51B	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 104.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	34
PHASE1	30
Not specified	18
PHASE1/PHASE2	17
EARLY_PHASE1	3
PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00770809	PHASE3	COMPLETED	Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery
NCT01638247	PHASE3	COMPLETED	Tamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients
NCT03384914	PHASE2	ACTIVE_NOT_RECRUITING	Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer
NCT05501704	PHASE2	RECRUITING	ETHAN - ET for Male BC
NCT00003199	PHASE2	COMPLETED	Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer
NCT00005817	PHASE2	COMPLETED	Rebeccamycin Analogue in Treating Women With Stage IIIB or Stage IV Breast Cancer
NCT00006228	PHASE2	COMPLETED	Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer
NCT00017394	PHASE2	COMPLETED	Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast Cancer
NCT00024154	PHASE2	COMPLETED	Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast Cancer
NCT00045188	PHASE2	COMPLETED	Imatinib Mesylate in Treating Patients With Metastatic Breast Cancer
NCT00063934	PHASE1/PHASE2	TERMINATED	Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer
NCT00068588	PHASE2	COMPLETED	GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer
NCT00070252	PHASE1/PHASE2	COMPLETED	Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer
NCT00077376	PHASE2	COMPLETED	Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer
NCT00095888	PHASE2	TERMINATED	3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer
NCT00096434	PHASE2	COMPLETED	Sorafenib in Treating Patients With Metastatic Breast Cancer
NCT00098397	PHASE2	COMPLETED	FR901228 in Treating Patients With Metastatic Breast Cancer
NCT00098605	PHASE2	COMPLETED	Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases
NCT00118157	PHASE2	COMPLETED	Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen
NCT00119262	PHASE2	COMPLETED	Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer
NCT00132002	PHASE2	TERMINATED	Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast Cancer
NCT00244881	PHASE2	COMPLETED	A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)
NCT00258349	PHASE1/PHASE2	COMPLETED	Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast Cancer
NCT00331552	PHASE1/PHASE2	COMPLETED	Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer
NCT00343109	PHASE2	COMPLETED	Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer
NCT00368875	PHASE1/PHASE2	COMPLETED	Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer
NCT00425672	PHASE1/PHASE2	COMPLETED	ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment
NCT00470301	PHASE1/PHASE2	COMPLETED	Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer
NCT00513695	PHASE2	COMPLETED	Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer
NCT00559507	PHASE2	COMPLETED	Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery
NCT00699491	PHASE1/PHASE2	COMPLETED	Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
NCT00791037	PHASE1/PHASE2	COMPLETED	Vaccine Therapy in Treating Patients With Stage IV Breast Cancer
NCT00821964	PHASE2	COMPLETED	Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer
NCT00861705	PHASE2	COMPLETED	Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery
NCT01037790	PHASE2	COMPLETED	Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
NCT01042535	PHASE1/PHASE2	COMPLETED	Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer
NCT01100489	PHASE2	WITHDRAWN	Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer
NCT01151449	PHASE2	TERMINATED	Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer
NCT01217411	PHASE1/PHASE2	TERMINATED	RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer
NCT01349959	PHASE2	COMPLETED	Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
LAPATINIB	4	13
TAMOXIFEN CITRATE	4	5
VORINOSTAT	4	3
ALDESLEUKIN	4	2
FLUOROESTRADIOL F-18	4	2
PAZOPANIB HYDROCHLORIDE	4	2
PEGFILGRASTIM	4	2
ROMIDEPSIN	4	2
BUSULFAN	4	1
DEGARELIX	4	1
DENILEUKIN DIFTITOX	4	1
EPIRUBICIN HYDROCHLORIDE	4	1
ERIBULIN MESYLATE	4	1
ERLOTINIB HYDROCHLORIDE	4	1
EXEMESTANE	4	1
GEFITINIB	4	1
GOSERELIN ACETATE	4	1
IMATINIB MESYLATE	4	1
IMIQUIMOD	4	1
IXABEPILONE	4	1
ONDANSETRON HYDROCHLORIDE	4	1
PALBOCICLIB	4	1
PALONOSETRON HYDROCHLORIDE	4	1
SARGRAMOSTIM	4	1
SORAFENIB	4	1
SORAFENIB TOSYLATE	4	1
SUNITINIB MALATE	4	1
TAMOXIFEN	4	1
TEMSIROLIMUS	4	1
THIOTEPA	4	1